摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-pyridin-4-ylethynyl-1,2,8,11,12,13,14,15,16,17-decahydro-6H-7-oxacyclopenta[a]phenanthren-3-one

中文名称
——
中文别名
——
英文名称
(8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-pyridin-4-ylethynyl-1,2,8,11,12,13,14,15,16,17-decahydro-6H-7-oxacyclopenta[a]phenanthren-3-one
英文别名
(1S,3aR,3bS,10R,11aS)-10-[4-(dimethylamino)phenyl]-1-hydroxy-11a-methyl-1-(2-pyridin-4-ylethynyl)-3,3a,3b,5,8,9,10,11-octahydro-2H-indeno[4,5-c]isochromen-7-one
(8S,11S,13S,14R,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-pyridin-4-ylethynyl-1,2,8,11,12,13,14,15,16,17-decahydro-6H-7-oxacyclopenta[a]phenanthren-3-one化学式
CAS
——
化学式
C32H34N2O3
mdl
——
分子量
494.634
InChiKey
AAKKTJVHZGBWLJ-AKOOALSVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    37
  • 可旋转键数:
    4
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    62.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为产物:
    参考文献:
    名称:
    Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists
    摘要:
    Efficient parallel synthesis of novel 7-oxa-steroids 4 has been achieved from the key intermediate 3 via a one-pot four-step sequence. oxa-Steroids 4 with various ortho-, meta-, and para-monosubstituents on the phenyl ring, as well as disubstituted phenyl and heterocycles, were evaluated for progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist activities. SAR study demonstrated that the para-fluorinated substituents on the phenyl ring not only increased the potency for PR in a T47D cell functional assay, but also improved the selectivity over GR in an A549 cell functional assay. The para-fluorophenyl oxa-steroid 41 and the para-trifluoromethylphenyl oxa-steroid 4p were found to be remarkably more potent and more selective PR antagonists than mifepristone, with subnanomolar potency and about 140-fold selectivity over GR. Molecular modeling of the oxa-steroid bound to PR provided meaningful insight for the SAR study. oxa-Steroids 4a and 4b were found to be more efficacious than mifepristone in vivo in a rat uterine complement C3 assay via the oral route, although they were less than or equally potent to mifepristone in the T47D assay. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.02.013
点击查看最新优质反应信息

文献信息

  • Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists
    作者:Fu-An Kang、Jihua Guan、Nareshkumar Jain、George Allan、Olivia Linton、Pamela Tannenbaum、Xin Chen、Jun Xu、Peifang Zhu、Joseph Gunnet、Keith Demarest、Scott Lundeen、Zhihua Sui
    DOI:10.1016/j.bmcl.2007.02.013
    日期:2007.5
    Efficient parallel synthesis of novel 7-oxa-steroids 4 has been achieved from the key intermediate 3 via a one-pot four-step sequence. oxa-Steroids 4 with various ortho-, meta-, and para-monosubstituents on the phenyl ring, as well as disubstituted phenyl and heterocycles, were evaluated for progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist activities. SAR study demonstrated that the para-fluorinated substituents on the phenyl ring not only increased the potency for PR in a T47D cell functional assay, but also improved the selectivity over GR in an A549 cell functional assay. The para-fluorophenyl oxa-steroid 41 and the para-trifluoromethylphenyl oxa-steroid 4p were found to be remarkably more potent and more selective PR antagonists than mifepristone, with subnanomolar potency and about 140-fold selectivity over GR. Molecular modeling of the oxa-steroid bound to PR provided meaningful insight for the SAR study. oxa-Steroids 4a and 4b were found to be more efficacious than mifepristone in vivo in a rat uterine complement C3 assay via the oral route, although they were less than or equally potent to mifepristone in the T47D assay. (c) 2007 Elsevier Ltd. All rights reserved.
查看更多